FDA Approves Augtyro (repotrectinib) for Adults and Children with NTRK-Positive Solid Tumors
On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and...
On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerate...
